U.S. markets closed
  • S&P Futures

    3,839.50
    +20.25 (+0.53%)
     
  • Dow Futures

    31,940.00
    +164.00 (+0.52%)
     
  • Nasdaq Futures

    12,395.00
    +97.75 (+0.79%)
     
  • Russell 2000 Futures

    2,212.70
    +11.90 (+0.54%)
     
  • Crude Oil

    65.47
    +0.42 (+0.65%)
     
  • Gold

    1,682.00
    +4.00 (+0.24%)
     
  • Silver

    25.26
    -0.00 (-0.02%)
     
  • EUR/USD

    1.1853
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3830
    +0.0008 (+0.06%)
     
  • USD/JPY

    109.1810
    +0.2800 (+0.26%)
     
  • BTC-USD

    53,371.62
    +1,679.30 (+3.25%)
     
  • CMC Crypto 200

    1,078.07
    +53.87 (+5.26%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,687.93
    -55.32 (-0.19%)
     

Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors in CRISPR Therapeutics AG CRSP need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 15, 2021 $90.00 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for CRISPR Therapeutics shares, but what is the fundamental picture for the company? Currently, CRISPR Therapeutics is a Zacks Rank #4 (Sell) in the Medical – Biomedical and Genetics industry that ranks in the Bottom 19% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while six have dropped their estimates. The net effect has widened our Zacks Consensus Estimate for the current quarter from a loss of $1.18 per share to a loss of $1.23 in that period.

Given the way analysts feel about CRISPR Therapeutics right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options?

Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.

Click to see the trades now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research